Discordance of PD-L1 expression between primary and paired metastatic non-small cell lung cancer: a systematic review and meta-analysis.
Cancer cells in different body locations vary in immune markers, suggesting doctors may need multiple tissue samples for optimal treatment planning.
PD-L1 expression in non-small cell lung cancer (NSCLC) serves as a key predictive biomarker of response to immune checkpoint inhibitors; however, the concordance of PD-L1 expression between primary tumors and their corresponding metastatic lesions remains uncertain. Fifteen studies fulfilled the inclusion criteria, encompassing 1,029 matched primary-metastatic sample pairs from 1,014 patients with NSCLC.
What the study was
- Study design
- Meta-analysis
- Population
- Patients with (see abstract)
- Sample size
- 14
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Frontiers in immunology
Why it surfaced
Meta-analysis (15 studies, 1,014 NSCLC patients) of PD-L1 expression discordance between primary and metastatic sites; directly impacts immunotherapy treatment decisions. Score=8/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.